
Morepen Laboratories Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
Yes
Order
Yes
Capex
Yes
4 of 5 growth signals are positive — a strong management growth story.
Full analysisRevenue guidance
Category 3- Morepen Laboratories targets a steady growth rate in revenue and volumes.
- API segment expected to grow at a CAGR of 17%-18%, potentially up to 20%-25% with capacity expansions.
- Medical devices showing strong growth, around 24% quarterly and 37% over nine months, with plans to increase distribution.
- Formulation business is a new growth driver, having grown 40% in the recent quarter, expected to double to around Rs.500 Crores in three years.
- Dr. Morepen OTC brand currently flat/fluctuating due to limited marketing investments but new innovative products are planned for launch.
- Overall growth target ranges from 20%-25% annually.
- Capacity expansions underway: Rs.125-150 Crores in API, Rs.50 Crores in medical devices, Rs.40 Crores in formulations.
- Focus on internal accruals for funding, with fundraising plans under evaluation.
- Aim to maintain and improve EBITDA and PAT margins with operational efficiencies and product mix improvements.
See what Morepen Laboratories management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- Morepen Laboratories is currently evaluating various fundraising options for resource augmentation, including capacity expansion and working capital needs.
- The company is debt-free and has been approached by multiple banks for debt raising; discussions are ongoing but no final decisions have been made yet.
- Future capex plans amount to Rs. 200 to 250 Crores over the next 2-3 years across API, medical devices, and formulations divisions, which may require additional financing.
- The financial team is working on finalizing plans, and the company is open to debt or equity fundraising depending on market conditions and performance.
- No specific details or timelines about new fundraising through debt or equity have been disclosed yet; the company is at an evaluation stage.
See what Morepen Laboratories management said on order book — free account, 30 seconds.
Capex plans
Yes- Capex plans span across API, medical devices, and formulations.
- API segment capex planned around Rs.125 Crores.
- Medical devices capex estimated at Rs.50 Crores.
- Formulation capex roughly Rs.40 Crores.
- Total capex plus working capital in next 2-3 years expected between Rs.200 Crores to Rs.250 Crores.
- Current capacity expansions funded from internal accruals (e.g., Rs.50 Crores spent in last 9 months).
- Additional API capacity planned: 250 KL within next 12 months.
- Working capital augmentation planned due to 20-25% expected growth.
- Company is debt-free but open to debt raising and evaluating multiple financing options.
- No final fundraising decisions yet; resource augmentation and capacity building are under evaluation.
- Focus on zero liquid discharge (ZLD) plant approval for environmental compliance.
Track Morepen Laboratories — get its next earnings analysis in your feed
How does Morepen Laboratories rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Morepen Laboratories rank in Pharmaceuticals & Biotechnology?
Compare Morepen Laboratories against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Morepen Laboratories's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem